A total of 580 patients were identified from HIRD by the algorithm. Of those, 510 cases had either neurologist or PCP/pediatrician involved during MD care and 204 cases were current active fully insured members allowed for chart studies. Among the 204 cases for which medical charts were requested, charts for 109 patients were obtained and reviewed by the nurse abstractors (53.4%, Table
1).
Male patients with ≥2 office visits with diagnosis of hereditary progressive MDa between 01/01/2013 and 12/31/2016 and < 18 years of age at time of first diagnosis | 580 |
Involvement of either neurologist or PCP/pediatrician during MD care | 510 |
Patients allowed for chart studies (e.g., current active fully insured members) | 204 |
Charts obtained and abstracted | 109 |
Characteristics of the patients whose medical charts were obtained are summarized in Table
2. The average age was 12.6 years (SD 4.97). Overall, 74 (67.9%) patients had at least one pediatric complex chronic condition (other than neurologic and neuromuscular disease) as measured by modified CCC. 54 (49.5%) had cardiovascular conditions; 14 (12.8%) had respiratory conditions; 50 (45.9%) had bone-related issues; 11 (10.1%) had impaired growth; and 6 (5.5%) had puberty delay. The average length of health plan coverage was 2.8 years. Throughout their health coverage, 27 (24.8%) patients had more than one inpatient hospitalization and 38 (34.9%) had more than one ED visit. In general, the characteristics of patients whose medical charts were unobtainable did not differ from those whose medical charts were obtained (Additional file
2: Table S2).
Table 2
Characteristics of Patients Whose Medical Charts Were Obtained for Chart Validation
Age, mean (SD) | 12.6 (4.97) |
Age category, n (%) |
< 4 (infants) | 3 (2.8) |
4–11 (children) | 44 (40.4) |
12–18 (adolescents) | 47 (43.1) |
≥ 19 (adults) | 15 (13.8) |
Racea, n (%) |
Caucasian/White | 34 (31.2) |
Black | 0 (0.0) |
Asian/Pacific Islander/native | 3 (2.8) |
Not documented | 72 (66.1) |
Ethnicitya, n (%) |
Hispanic | 3 (2.8) |
Non-Hispanic | 15 (13.8) |
Not documented | 91 (83.5) |
Census Region, n (%) |
Northeast | 17 (15.6) |
Midwest | 30 (27.5) |
South | 32 (29.4) |
West | 30 (27.5) |
Clinical history (claims) |
Length of medical enrollment in years, mean (SD) | 2.8 (1.23) |
Modified pediatric CCCb, mean (SD) | 1.2 (1.25) |
Modified pediatric CCC category, n (%) |
0 | 35 (32.1) |
1 or 2 | 58 (53.2) |
≥ 3 | 16 (14.7) |
Any pediatric CCCc, n (%) |
Cardiovascular | 54 (49.5) |
Respiratory | 14 (12.8) |
Gastrointestinal | 10 (9.2) |
Metabolic | 4 (3.7) |
Hematologic or immunologic | 3 (2.8) |
Renal and urologic | 3 (2.8) |
Other congenital or genetic defect | 43 (39.4) |
Malignancy | 4 (3.7) |
Bone health issue, n (%) | 50 (45.9) |
Impaired growth, n (%) | 11 (10.1) |
Puberty delay, n (%) | 6 (5.5) |
Apnea, n (%) | 4 (3.7) |
Medical utilization history (claims), n (%) |
Any hospitalization | 27 (24.8) |
Any ED visit | 38 (34.9) |
Any outpatient visit | 109 (100.0) |
PCP visits | 106 (97.2) |
Specialist visits | 109 (100.0) |
Cardiologist | 75 (68.8) |
Pulmonologist | 54 (49.5) |
The PPV of the case-identifying algorithm for MD was 95% (95% CI 88–98%, Table
3). Of the 103 confirmed MD cases, 87 patients (85%) had Duchenne or Becker MD (95% CI 76–91%); 76 patients (74%) had Duchenne MD (95% CI 64–82%), and 11 patients (11%) had Becker MD (95% CI 5–18%). Other less common types of MD included limb-girdle MD (4 patients), facioscapulohumeral MD (3 patients), Emery-Dreifuss MD (2 patients), congenital MD – unknown type (2 patients), progressive and/or hereditary MD – unknown type (2 patients), myotonic MD type 1 (1 patient), myotubular MD (1 patient), and Ulrich MD (1 patient).
Table 3
Summary of Validation Results – Positive Predictive Values
Muscular Dystrophy | 109 | 103 | 95 (88–98) |
Duchenne or Becker MD | 103 | 87 | 85 (76–91) |
Duchenne | 103 | 76 | 74 (64–82) |
Becker | 103 | 11 | 11 (5–18) |
Discussion
The results of this study demonstrate that the case-finding algorithm can accurately identify patients with MD, primarily Duchenne MD, within a large administrative database. There was only one other study by Soslow et al. that established a claim-based algorithm to identify patients with Becker and Duchenne muscular dystropy. They reported PPV of 77%, but one limitation of the study was that they only looked at hospital encounter data, thus potentially missing a big proportion of patients with MD [
12]. Our study was strengthened by the ability to capture events across physician office visits and hospital encounters. Our algorithm, which was constructed using a few items that are easily accessible from claims, achieved a PPV of 95% for MD and 85% for Becker and Duchenne MD. A deeper look into the types of MDs shows that majority of the cases were Duchenne MD (74%), followed by Becker (11%) and other MD types, consistent with known etiologies.
The algorithm achieved similar PPV for Becker and Duchenne MD when compared to the algorithm in Soslow et al.’s study. Yet, the two studies had employed different strategies to optimize the specificity of algorithms. In Soslow et al. study, patients with a change in primary diagnosis to a different 359.x code were excluded. An additional set of clinical characteristics was used to exclude MD other than Becker and Duchenne MD (e.g., patients with early mortality, in ventilatory support, or cardiovascular disease at a young age). Our algorithm required at least two office visits with MD diagnosis because it is widely known that using only one ICD diagnosis code to identify cases could introduce inaccuracy and false positives. Supporting evidence from previous studies has shown that use of two or more ICD diagnosis codes improves the PPV of case-finding algorithms [
9,
10].
Using longitudinal claims data, the study also depicted the characteristics of patients with MD. Progressive muscular damage and degeneration in patients with MD manifests in muscular weakness, motor delays, respiratory impairment, and cardiomyopathy. As the disease progresses, the susceptibility to respiratory infection, respiratory compromise, and cardiomyopathy increase. These were confirmed in our study population: the prevalence of cardiovascular diseases increased from 0% among patients younger than 4 years to 67% among patients age 19 years and older. Additionally, the prevalence of respiratory disease increased from 0% among patients younger than 4 years to 27% among those age 19 years and older (data not shown). The overall rate of cardiovascular disease was much higher in our study (49.5% vs. 29.7% in Soslow et al. study), mostly likely due to their exclusion of patients with cardiovascular disease in the young age. While Soslow et al.’s study primarily focused on cardiovascular morbidity, our study also looked at the bone health and endocrine-related comorbidities, which are common in patients with MD and exacerbated by glucocorticoid treatment [
5]. We observed that nearly half of our study population had bone-related conditions, and more than 10% had endocrine-related conditions. Using available claim information throughout their health plan coverage period, we were able to capture disease burden as well as healthcare utilization.
Anticipated emergence of genetic and molecular therapies, advances in rehabilitation therapies, and the invention of non-invasive prenatal testing for MDs spark many questions in the care of patients with MD, such as optimum timing for initiation of new therapies and optimal, personalized treatments [
5,
6]. Given the small patient pool available, clinical trials will be challenged recruiting populations to investigate these questions. Observational studies, such as those using claims data, have a great amount of utility in advancing the knowledge base of MD care. Claims data reflect the comorbidities, treatment patterns, and the safety and effectiveness of therapies in typical patients seen in real-world settings, providing insight into the actual burden of Duchenne MD.
The study has a few limitations. Firstly, the ICD9/10 diagnosis code available at the time of this study was a single code for general MD and it did not differentiate subtypes. Since claims do not contain adequate clinical information, our case-finding algorithm was unable to distinguish between subtypes. Specific ICD-10 codes for Duchenne/Becker MD and facioscapilohumeral MD are planned to be introduced in October 2018 [
13], which are expected to enhance future claims-based research by improving the homogeneity of study populations. Secondly, our study only sampled cases obtained from claims, and thus was unable to report negative predictive value and sensitivity. For rare conditions, the ideal chart review method is impractical given the large amount of medical charts to be reviewed. Alternatively, several sampling strategies to select code negative patients have been implemented by investigators and researchers, but they are prone to bias introduced by disproportional sampling of code positive and code negative patients [
14]. Our algorithm picked up 48% of the patients with at least 1 MD diagnosis code. The sensitivity of the algorithm is unknown and needs to be evaluated with further research. Thirdly, the chart validation study sampled cases who were all likely had MD according to the algorithm. As the chart reviewers were not blinded to the study design, bias may have been introduced to move the PPV upward. Fourthly, our study characterized the co-morbidity burdens of patients with MD using claims data. Prevalence may vary by the type of diagnostic instruments used to define disease, however claims-based definition generally doesn’t include such information. Claim-based diagnosis may also subject to claim coding omissions or errors. Lastly, our data were drawn from commercially insured members who may not be representative of members under government or public insurance coverage.